{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T13:47:25Z","timestamp":1770040045485,"version":"3.49.0"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.bbrc.2025.152953","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T23:03:03Z","timestamp":1762902183000},"page":"152953","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Cheminformatics-based analysis identified Novel compounds from Nelumbo nucifera as potential inhibitors targeting PI3k\/Akt\/mTOR Pathway of HR+\/HER2- subtype for Breast Cancer"],"prefix":"10.1016","volume":"791","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9299-1240","authenticated-orcid":false,"given":"Sk Faisal","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0800-5482","authenticated-orcid":false,"given":"Proja","family":"Barua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4236-9212","authenticated-orcid":false,"given":"Md Al","family":"Amin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4894-1785","authenticated-orcid":false,"given":"Rahnuma","family":"Tabassum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8753-9107","authenticated-orcid":false,"given":"Mir Mohammad Ehsanul","family":"Haque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9827-8928","authenticated-orcid":false,"given":"Lamia","family":"Islam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Md Shohel","family":"Hossain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5380-0026","authenticated-orcid":false,"given":"Abhishek Kumar","family":"Verma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.bbrc.2025.152953_bib1","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.gendis.2018.05.001","article-title":"Breast cancer development and progression: risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis","volume":"5","author":"Feng","year":"2018","journal-title":"Genes Dis."},{"key":"10.1016\/j.bbrc.2025.152953_bib2","first-page":"2423","article-title":"Breast cancer: an overview","author":"Manoharan","year":"2010","journal-title":"Cell Tissue Res."},{"issue":"10352","key":"10.1016\/j.bbrc.2025.152953_bib3","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0140-6736(22)01438-6","article-title":"The global burden of cancer attributable to risk factors, 2010\u201319: a systematic analysis for the global burden of disease study 2019","volume":"400","author":"Tran","year":"2022","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.bbrc.2025.152953_bib4","doi-asserted-by":"crossref","first-page":"6834","DOI":"10.3390\/ijms24076834","article-title":"A basic review on estrogen receptor signaling pathways in breast cancer","volume":"24","author":"Clusan","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.bbrc.2025.152953_bib5","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.bbrc.2025.152953_bib6","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jss.2013.06.041","article-title":"Dasatinib is synergistic with cetuximab and cisplatin in triple-negative breast cancer cells","volume":"185","author":"Kim","year":"2013","journal-title":"J. Surg. Res."},{"issue":"10","key":"10.1016\/j.bbrc.2025.152953_bib7","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1093\/aje\/kwp036","article-title":"Breast cancer risk factors defined by estrogen and progesterone receptor status: the multiethnic cohort study","volume":"169","author":"Setiawan","year":"2009","journal-title":"Am. J. Epidemiol."},{"issue":"5","key":"10.1016\/j.bbrc.2025.152953_bib8","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju055","article-title":"US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status","volume":"106","author":"Howlader","year":"2014","journal-title":"JNCI J. Natl. Cancer Inst."},{"issue":"2","key":"10.1016\/j.bbrc.2025.152953_bib9","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1210\/er.2006-0045","article-title":"Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance","volume":"29","author":"Arpino","year":"2008","journal-title":"Endocr. Rev."},{"issue":"3","key":"10.1016\/j.bbrc.2025.152953_bib10","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/nrc1819","article-title":"Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis","volume":"6","author":"Cully","year":"2006","journal-title":"Nat. Rev. Cancer"},{"issue":"41","key":"10.1016\/j.bbrc.2025.152953_bib11","doi-asserted-by":"crossref","first-page":"5497","DOI":"10.1038\/onc.2008.245","article-title":"PI3K pathway alterations in cancer: variations on a theme","volume":"27","author":"Yuan","year":"2008","journal-title":"Oncogene"},{"issue":"7","key":"10.1016\/j.bbrc.2025.152953_bib12","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1172\/JCI41680","article-title":"Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor\u2013positive human breast cancer","volume":"120","author":"Miller","year":"2010","journal-title":"J. Clin. Investig."},{"issue":"283","key":"10.1016\/j.bbrc.2025.152953_bib13","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa4442","article-title":"PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor\u2013positive breast cancer","volume":"7","author":"Bosch","year":"2015","journal-title":"Sci. Transl. Med."},{"issue":"33","key":"10.1016\/j.bbrc.2025.152953_bib14","doi-asserted-by":"crossref","first-page":"4452","DOI":"10.1200\/JCO.2010.34.4879","article-title":"Phosphatidylinositol 3-Kinase and Antiestrogen resistance in breast cancer","volume":"29","author":"Miller","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.bbrc.2025.152953_bib15","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/s41580-019-0129-z","article-title":"PI3K isoforms in cell signalling and vesicle trafficking","volume":"20","author":"Bilanges","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"5","key":"10.1016\/j.bbrc.2025.152953_bib16","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nrm2882","article-title":"The emerging mechanisms of isoform-specific PI3K signalling","volume":"11","author":"Vanhaesebroeck","year":"2010","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"4","key":"10.1016\/j.bbrc.2025.152953_bib17","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1177\/1758834014530023","article-title":"The PI3K\/AKT\/mTOR pathway in breast cancer: targets, trials and biomarkers","volume":"6","author":"Paplomata","year":"2014","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.bbrc.2025.152953_bib18","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.5092","article-title":"The impact of PI3K inhibitors on breast cancer cell and its tumor microenvironment","volume":"6","author":"Qin","year":"2018","journal-title":"PeerJ"},{"issue":"3","key":"10.1016\/j.bbrc.2025.152953_bib19","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1158\/1535-7163.MCT-10-0994","article-title":"PIK3CA mutations in patients with advanced cancers treated with PI3K\/AKT\/mTOR axis inhibitors","volume":"10","author":"Janku","year":"2011","journal-title":"Mol. Cancer Therapeut."},{"issue":"1","key":"10.1016\/j.bbrc.2025.152953_bib20","doi-asserted-by":"crossref","DOI":"10.1080\/14756366.2023.2237209","article-title":"Inhibitors of phosphoinositide 3-kinase (PI3K) and phosphoinositide 3-kinase-related protein kinase family (PIKK)","volume":"38","author":"Huang","year":"2023","journal-title":"J. Enzym. Inhib. Med. Chem."},{"issue":"D1","key":"10.1016\/j.bbrc.2025.152953_bib21","doi-asserted-by":"crossref","first-page":"D777","DOI":"10.1093\/nar\/gkw1121","article-title":"COSMIC: somatic cancer genetics at high-resolution","volume":"45","author":"Forbes","year":"2017","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.bbrc.2025.152953_bib22","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.gde.2009.11.002","article-title":"Targeting the PI3K signaling pathway in cancer","volume":"20","author":"Wong","year":"2010","journal-title":"Curr. Opin. Genet. Dev."},{"issue":"6","key":"10.1016\/j.bbrc.2025.152953_bib23","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1200\/JCO.2009.25.3641","article-title":"The PI3K pathway as drug target in human cancer","volume":"28","author":"Courtney","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.bbrc.2025.152953_bib24","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1200\/JCO.2011.38.7167","article-title":"Phosphatidylinositide-3-Kinase inhibitors: addressing questions of isoform selectivity and Pharmacodynamic\/Predictive biomarkers in early clinical trials","volume":"30","author":"Clarke","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"7484","key":"10.1016\/j.bbrc.2025.152953_bib25","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature12912","article-title":"Discovery and saturation analysis of cancer genes across 21 tumour types","volume":"505","author":"Lawrence","year":"2014","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.bbrc.2025.152953_bib26","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.4161\/cc.3.10.1164","article-title":"Oncogenic mutations of PIK3CA in human cancers","volume":"3","author":"Samuels","year":"2004","journal-title":"Cell Cycle"},{"key":"10.1016\/j.bbrc.2025.152953_bib27","article-title":"FDA approves alpelisib for metastatic breast cancer","year":"2019","journal-title":"Case Med. Res."},{"issue":"13","key":"10.1016\/j.bbrc.2025.152953_bib28","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1200\/JCO.2017.72.7107","article-title":"Phosphatidylinositol 3-Kinase \u03b1\u2013Selective inhibition with Alpelisib (BYL719) in PIK3CA -Altered solid tumors: results from the first-in-human Study","volume":"36","author":"Juric","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"41","key":"10.1016\/j.bbrc.2025.152953_bib29","doi-asserted-by":"crossref","first-page":"5486","DOI":"10.1038\/onc.2008.244","article-title":"Class I PI3K in oncogenic cellular transformation","volume":"27","author":"Zhao","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.bbrc.2025.152953_bib30","first-page":"1","article-title":"New perspectives on how to discover drugs from herbal medicines: cam's outstanding contribution to modern therapeutics","volume":"2013","author":"Pan","year":"2013","journal-title":"Evid. Based Complement. Altern. Med."},{"key":"10.1016\/j.bbrc.2025.152953_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/721402","article-title":"Evaluating medicinal plants for anticancer activity","volume":"2014","author":"Solowey","year":"2014","journal-title":"Sci. World J."},{"issue":"1","key":"10.1016\/j.bbrc.2025.152953_bib32","doi-asserted-by":"crossref","first-page":"175","DOI":"10.30574\/gscbps.2022.21.1.0395","article-title":"Investigation of aquatic vascular flora at Sadullapur Upazila of Gaibandha district, Bangladesh","volume":"21","author":"Akter Ame","year":"2022","journal-title":"GSC Biol. Pharm. Sci."},{"key":"10.1016\/j.bbrc.2025.152953_bib33","series-title":"Aquatic Medicinal Plants","first-page":"1","article-title":"Phytochemicals and medicinal importance of Nelumbo nucifera","author":"Das","year":"2023"},{"issue":"1","key":"10.1016\/j.bbrc.2025.152953_bib34","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-40160-2","article-title":"Molecular docking as a tool for the discovery of molecular targets of nutraceuticals in diseases management","volume":"13","author":"Agu","year":"2023","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.bbrc.2025.152953_bib35","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s12094-015-1410-z","article-title":"Inhibiting the PI3K signaling pathway: buparlisib as a new targeted option in breast carcinoma","volume":"18","author":"Est\u00e9vez","year":"2016","journal-title":"Clin. Transl. Oncol."},{"issue":"10","key":"10.1016\/j.bbrc.2025.152953_bib36","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1021\/ci1002679","article-title":"Docking studies on isoform-specific inhibition of Phosphoinositide-3-Kinases","volume":"50","author":"Sabbah","year":"2010","journal-title":"J. Chem. Inf. Model."},{"issue":"10","key":"10.1016\/j.bbrc.2025.152953_bib37","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1080\/13543776.2021.1924150","article-title":"Phosphatidylinositol 3-kinase (PI3K) inhibitors: a recent update on inhibitor design and clinical trials (2016\u20132020)","volume":"31","author":"Sabbah","year":"2021","journal-title":"Expert Opin. Ther. Pat."},{"issue":"2","key":"10.1016\/j.bbrc.2025.152953_bib38","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.bmcl.2011.12.044","article-title":"Biological evaluation and docking studies of recently identified inhibitors of phosphoinositide-3-kinases","volume":"22","author":"Sabbah","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"4","key":"10.1016\/j.bbrc.2025.152953_bib39","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbaa279","article-title":"InstaDock: a single-click graphical user interface for molecular docking-based virtual high-throughput screening","volume":"22","author":"Mohammad","year":"2021","journal-title":"Briefings Bioinf."},{"issue":"2","key":"10.1016\/j.bbrc.2025.152953_bib40","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J. Comput. Chem."},{"issue":"1","key":"10.1016\/j.bbrc.2025.152953_bib41","doi-asserted-by":"crossref","DOI":"10.1038\/srep42717","article-title":"SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci. Rep."},{"issue":"W1","key":"10.1016\/j.bbrc.2025.152953_bib42","doi-asserted-by":"crossref","first-page":"W513","DOI":"10.1093\/nar\/gkae303","article-title":"ProTox 3.0: a webserver for the prediction of toxicity of chemicals","volume":"52","author":"Banerjee","year":"2024","journal-title":"Nucleic Acids Res."},{"issue":"12","key":"10.1016\/j.bbrc.2025.152953_bib43","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1177\/009127000004001211","article-title":"Pharmacokinetic\/Pharmacodynamic modeling in drug research and development","volume":"40","author":"Derendorf","year":"2000","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.bbrc.2025.152953_bib44","volume":"201","author":"Frisch","year":"2009","journal-title":"Gaussian 09, Revision d. 01, Gaussian,\u201d Inc, Wallingford CT"},{"key":"10.1016\/j.bbrc.2025.152953_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2024\/5554208","article-title":"Genome-Wide investigation reveals potential therapeutic targets in Shigella spp","volume":"2024","author":"Hossain","year":"2024","journal-title":"BioMed Res. Int."},{"issue":"10","key":"10.1016\/j.bbrc.2025.152953_bib46","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1002\/jcc.21787","article-title":"MDAnalysis: a toolkit for the analysis of molecular dynamics simulations","volume":"32","author":"Michaud\u2010Agrawal","year":"2011","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.bbrc.2025.152953_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.imu.2021.100777","article-title":"In silico identification of potential inhibitors with higher potency than bumetanide targeting NKCC1: an important ion co-transporter to treat neurological disorders","volume":"27","author":"Roy","year":"2021","journal-title":"Inform. Med. Unlocked"},{"key":"10.1016\/j.bbrc.2025.152953_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2020.104185","article-title":"Identification of FDA approved drugs and nucleoside analogues as potential SARS-CoV-2 A1pp domain inhibitor: an in silico study","volume":"130","author":"Singh","year":"2021","journal-title":"Comput. Biol. Med."},{"key":"10.1016\/j.bbrc.2025.152953_bib49","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.compbiolchem.2017.08.006","article-title":"Molecular dynamics-assisted pharmacophore modeling of caspase-3-isatin sulfonamide complex: recognizing essential intermolecular contacts and features of sulfonamide inhibitor class for caspase-3 binding","volume":"71","author":"Kumar","year":"2017","journal-title":"Comput. Biol. Chem."},{"issue":"10","key":"10.1016\/j.bbrc.2025.152953_bib50","doi-asserted-by":"crossref","first-page":"4361","DOI":"10.1021\/acs.jcim.9b00433","article-title":"Structural and dynamical basis of G protein inhibition by YM-254890 and FR900359: an inhibitor in action","volume":"59","author":"Tietze","year":"2019","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.bbrc.2025.152953_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.imu.2024.101549","article-title":"In silico computational prediction of Saussurea pulchella compounds with inhibitory effects on plasmepsin X in Plasmodium falciparum","volume":"49","author":"Gholam","year":"2024","journal-title":"Inform. Med. Unlocked"},{"issue":"24","key":"10.1016\/j.bbrc.2025.152953_bib52","doi-asserted-by":"crossref","first-page":"6256","DOI":"10.3390\/ijms20246256","article-title":"Structural and dynamic characterizations highlight the deleterious role of SULT1A1 R213H polymorphism in substrate binding","volume":"20","author":"Dash","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.bbrc.2025.152953_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.arabjc.2021.103315","article-title":"Antiviral peptides against the main protease of SARS-CoV-2: a molecular docking and dynamics study","volume":"14","author":"Mahmud","year":"2021","journal-title":"Arab. J. Chem."},{"key":"10.1016\/j.bbrc.2025.152953_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.imu.2021.100748","article-title":"In silico analysis of ciprofloxacin analogs as inhibitors of DNA gyrase of Staphylococcus aureus","volume":"26","author":"Hasan","year":"2021","journal-title":"Inform. Med. Unlocked"},{"key":"10.1016\/j.bbrc.2025.152953_bib55","series-title":"Principal Component Analysis as a Tool for Library Design: a Case Study Investigating Natural Products, Brand-Name Drugs, Natural Product-like Libraries, and Drug-like Libraries","first-page":"225","author":"Wenderski","year":"2015"},{"issue":"1","key":"10.1016\/j.bbrc.2025.152953_bib56","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-52308-0","article-title":"Prediction of deleterious non-synonymous SNPs of Human STK11 gene by combining algorithms, molecular docking, and molecular dynamics simulation","volume":"9","author":"Islam","year":"2019","journal-title":"Sci. Rep."},{"issue":"10","key":"10.1016\/j.bbrc.2025.152953_bib57","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0240004","article-title":"In-silico design of a potential inhibitor of SARS-CoV-2 S protein","volume":"15","author":"Jaiswal","year":"2020","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.bbrc.2025.152953_bib58","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1021\/jf103488j","article-title":"(\u2212)-Anonaine induces DNA damage and inhibits growth and migration of human lung carcinoma H1299 cells","volume":"59","author":"Chen","year":"2011","journal-title":"J. Agric. Food Chem."},{"issue":"1","key":"10.1016\/j.bbrc.2025.152953_bib59","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0378-8741(92)90058-Y","article-title":"Antimicrobial activity of benzylisoquinoline alkaloids from Annona salzmanii D.C","volume":"36","author":"Paulo","year":"1992","journal-title":"J. Ethnopharmacol."},{"issue":"3","key":"10.1016\/j.bbrc.2025.152953_bib60","first-page":"132","article-title":"Screening of isoquinoline alkaloids and their derivatives for antibacterial and antifungal activities","volume":"5","author":"Tsai","year":"1989","journal-title":"Gaoxiong Yi Xue Ke Xue Za Zhi"},{"issue":"4","key":"10.1016\/j.bbrc.2025.152953_bib61","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1021\/np50118a021","article-title":"(-)-Roemerine, an aporphine alkaloid from Annona senegalensis that reverses the multidrug-resistance phenotype with cultured cells","volume":"58","author":"You","year":"1995","journal-title":"J. Nat. Prod."},{"issue":"3","key":"10.1016\/j.bbrc.2025.152953_bib62","doi-asserted-by":"crossref","first-page":"554","DOI":"10.3390\/vaccines11030554","article-title":"Therapeutic potential of Luteolin on cancer","volume":"11","author":"\u00c7etinkaya","year":"2023","journal-title":"Vaccines"},{"issue":"7","key":"10.1016\/j.bbrc.2025.152953_bib63","doi-asserted-by":"crossref","first-page":"634","DOI":"10.2174\/156800908786241050","article-title":"Luteolin, a flavonoid with potential for cancer prevention and therapy","volume":"8","author":"Lin","year":"2008","journal-title":"Curr. Cancer Drug Targets"},{"issue":"10","key":"10.1016\/j.bbrc.2025.152953_bib64","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.3390\/cancers11101494","article-title":"Isorhamnetin induces cell cycle arrest and apoptosis via reactive oxygen species-mediated AMP-Activated protein kinase signaling pathway activation in human bladder cancer cells","volume":"11","author":"Park","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.bbrc.2025.152953_bib65","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.3390\/ijms24032952","article-title":"Targets involved in the anti-cancer activity of Quercetin in breast, colorectal and liver neoplasms","volume":"24","author":"Maugeri","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbrc.2025.152953_bib66","first-page":"23","article-title":"Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date","volume":"10","author":"Criscitiello","year":"2018","journal-title":"Breast Cancer"},{"issue":"12","key":"10.1016\/j.bbrc.2025.152953_bib67","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0260853","article-title":"Pharmacokinetics and drug-likeness of antidiabetic flavonoids: molecular docking and DFT study","volume":"16","author":"Bitew","year":"2021","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.bbrc.2025.152953_bib68","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1007\/s13197-013-1105-9","article-title":"GC-MS analysis of bioactive compounds from the whole plant ethanolic extract of Evolvulus alsinoides (L.) L","volume":"52","author":"Gomathi","year":"2015","journal-title":"J. Food Sci. Technol."},{"issue":"5","key":"10.1016\/j.bbrc.2025.152953_bib69","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1002\/etc.4988","article-title":"Assessing the toxicity of individual aromatic compounds and mixtures to American lobster (Homarus americanus) larvae using a passive dosing system","volume":"40","author":"Philibert","year":"2021","journal-title":"Environ. Toxicol. Chem."},{"issue":"6","key":"10.1016\/j.bbrc.2025.152953_bib70","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0326655","article-title":"Computational design and cheminformatics profiling of omeprazole derivatives for enhanced proton pump inhibition of potassium-transporting ATPase alpha chain 1","volume":"20","author":"Hasan","year":"2025","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.bbrc.2025.152953_bib71","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s40203-021-00102-0","article-title":"In silico DFT study, molecular docking, and ADMET predictions of cytidine analogs with antimicrobial and anticancer properties","volume":"9","author":"Rana","year":"2021","journal-title":"Silico Pharmacol."},{"issue":"4","key":"10.1016\/j.bbrc.2025.152953_bib72","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/prot.340170408","article-title":"Essential dynamics of proteins","volume":"17","author":"Amadei","year":"1993","journal-title":"Proteins: Struct., Funct., Bioinf."},{"issue":"10","key":"10.1016\/j.bbrc.2025.152953_bib73","doi-asserted-by":"crossref","first-page":"4292","DOI":"10.1007\/s12010-022-03893-w","article-title":"In silico and in vitro evaluations of fluorophoric Thiazolo-[2,3-b]quinazolinones as anti-cancer agents targeting EGFR-TKD","volume":"194","author":"Mir","year":"2022","journal-title":"Appl. Biochem. Biotechnol."},{"issue":"3","key":"10.1016\/j.bbrc.2025.152953_bib74","article-title":"Breast cancer: a review of risk factors and diagnosis","volume":"103","author":"Obeagu","year":"2024","journal-title":"Medicine (Baltim.)"},{"issue":"4","key":"10.1016\/j.bbrc.2025.152953_bib75","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s12282-024-01567-5","article-title":"PI3K\/AKT\/mTOR signaling pathway: an important driver and therapeutic target in triple-negative breast cancer","volume":"31","author":"Zhang","year":"2024","journal-title":"Breast Cancer"}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X25016699?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X25016699?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T17:14:29Z","timestamp":1766078069000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X25016699"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":75,"alternative-id":["S0006291X25016699"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2025.152953","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cheminformatics-based analysis identified Novel compounds from Nelumbo nucifera as potential inhibitors targeting PI3k\/Akt\/mTOR Pathway of HR+\/HER2- subtype for Breast Cancer","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2025.152953","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"152953"}}